Navigation Links
How one virus uses mimicry to replicate successfully
Date:10/31/2007

(PHILADELPHIA) Both viruses and cancers subvert the growth-control machinery in a cell to serve their own needs. According to a new study, at least one virus uses mimicry to gain access to that machinery.

A common target for both is a cell protein called the retinoblastoma protein, or pRb, which serves to block cell division when potentially cancer-causing gene mutations are present. First identified in pediatric tumors of the retina, this tumor suppressor protein has since been found to play a role in many other forms of cancer when disrupted.

A number of viruses produce proteins that specifically target pRb, and scientists have studied these viruses and their proteins closely to better understand how normal cells can turn cancerous. Among such viruses are the adenoviruses, which produce a protein called E1A that interferes with pRb and its ability to control unwanted cell division. Adenoviruses are not themselves cancer causing, but a better understanding of how they interact with pRb might well shed light on related mechanisms used by other viruses to trigger cancers. For example, a protein that is functionally equivalent to E1A from human papillomavirus, called E7, causes cervical cancer in the cells it infects.

Until now, investigators had been unable to obtain detailed information about how E1A disrupts the normal function of pRb. In a new study, however, featured on the cover of the November 1 issue of the journal Genes & Development, researchers at The Wistar Institute have solved the three-dimensional structure of a molecular complex of pRb and E1A, providing the first atomic view of the viral E1A protein in action.

The findings show that that E1A operates in a novel way, mimicking a normal cellular protein called E2F that ordinarily binds to pRb in a controlled and regulated fashion.

The structural similarities between E1A and E2F are surprising and striking, says Ronen Marmorstein, Ph.D., a professor in the Gene Expression and Regulation Program at Wistar and senior author on the study. Looking at the structure it became obvious how this viral protein disrupts the activity of pRb.

pRb is a member of the pocket-protein family, because it has a pocket within which proteins can bind. For pRb to function normally, it needs to bind a molecular complex incorporating the E2F protein. When pRb is bound to this complex, it acts as a growth suppressor, inhibiting cell division.

In their study, Marmorstein and a colleague showed that E1A disables pRb and its ability to control cell division by mimicking E2F and occupying the same pocket where E2F would normally bind.

Looking at the structure, we see that the E1A protein displaces E2F by binding to a specific location on pRb, Marmorstein says. By knocking out pRb in this manner, E1A forces cells to start dividing uncontrollably, a hallmark of cancer.

This approach to targeting pRb is quite different from methods used by other viral proteins, he adds.

The study provides the first structural information on the E1A protein. In developing the required crystals for the structure determination, Xin Liu, the lead author on the study, first had to identify suitable binding partners for the protein.

Because E1A is so flexible, it needs binding partners to crystallize, Liu says.

By forming a complex with pRb and these binding partners, the researchers were able to crystallize the protein and then analyze its structure using a technique called X-ray crystallography. Their studies revealed how each component of the complex worked in three-dimensional detail.

The scientists are now working to analyze the structure of larger regions of the E1A protein bound to pRb and other cellular E1A targets to more fully characterize how this viral mechanism might cause cancer.


'/>"/>

Contact: Franklin Hoke
hoke@wistar.org
215-898-3716
The Wistar Institute
Source:Eurekalert

Related medicine news :

1. Virus Level could Predict Cervical Cancer Risk
2. Ebola Virus - Outbreak Claims More Lives In Uganda.
3. Experimental treatment for Ebola Virus Shows promising results in mice
4. Virus Combats Brain Tumour
5. Virus killer
6. Minor mutations in HIV virus
7. Virus makes Hodgkin’s disease more deadl
8. Infertility in relation with virus
9. Birds breed viruses
10. Hidden influenza virus protein found
11. Pain Killers Keep the Virus Away
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. ... Board of Dermatology and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology ... Dr. Li completed his internship in internal medicine at the Emory University and ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... now offering treatments for patients with sleep apnea and TMJ disorders. These conditions ... and physical health. Dr. Rassouli provides personalized care to reduce the risk of ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree ... planning services to communities throughout eastern Georgia, is embarking on a charity effort ... Heart disease kills more Americans every year than anything else, yet risk factors ...
(Date:1/19/2017)... ... January 19, 2017 , ... Creative messages ... Real Impact contest from Impact Teen Drivers and California Casualty. Entries from students ... , Educational grants totaling $15,000 will be awarded for the best peer-to-peer messages ...
(Date:1/19/2017)... ... , ... The 21st Century Cures Act’s Impact on Medical Devices:, What You ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , What do ... this year? , The passage of the act means devicemakers will be scrambling to ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- , , Marks E-QURE , ... distribution agreement, following similar agreements in Israel and ... 5 billion global market ... a leader in medical devices for the treatment of advanced wound care, announced ... (TeckMedica) in Colombia for the Company,s patented Bio-electrical Signal ...
(Date:1/19/2017)... ALAMEDA, Calif. , Jan. 18, 2017 /PRNewswire/ ... (MPI) solutions has entered into an agreement with ... for the Momentum MPI imaging system based on ... VivoQuant will be distributed as a complete MPI ... to enable quantitative nanoparticle or cell imaging in ...
(Date:1/19/2017)... , Jan. 18, 2017 The Academy ... and Drug Administration (FDA) for its release today ... population health decision makers can proactively share clinical ... as well as emerging therapies awaiting FDA approval. ... consensus recommendations that AMCP developed during two multi-stakeholder ...
Breaking Medicine Technology: